Printer Friendly

XOMA VICTORY IN PATENT SUIT SUSTAINED

 XOMA VICTORY IN PATENT SUIT SUSTAINED
 BERKELEY, Calif., Jan. 31 /PRNewswire/ -- A U.S. District Court


judge in San Francisco has sustained a jury verdict in favor of XOMA Corp. (NASDAQ: XOMA) in its patent infringement suit against Centocor Inc. (Malvern, Pa.). The Honorable Robert H. Schnacke, who presided over the jury trial, today denied a motion filed by Centocor to set aside the jury verdict.
 XOMA filed suit against Centocor in April 1990 for infringement of U.S. Patent No. 4,918,163 which covers the use of certain anti- endotoxin monoclonal antibodies in the treatment of humans with gram- negative sepsis. The patent is licensed exclusively to XOMA by the University of California. In a trial that was held in the U.S. District Court for the Northern District of California, a jury found that Centocor infringes the patent. The trial was completed in October 1991.
 XOMA Corp. is a leading company in the development of therapeutic products using monoclonal antibody and recombinant DNA technologies.
 -0- 1/31/92
 /CONTACT: Carol D. DeGuzman of XOMA Corp., 510-644-1170; or Diana Dalsass or Mike Millican of Robert Marston and Associates, 212-371-2200, for XOMA Corp./
 (XOMA) CO: XOMA Corp. ST: California IN: MTC SU:


RM -- SF007 -- 5734 01/31/92 15:39 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 31, 1992
Words:212
Previous Article:BANNER AEROSPACE ANNOUNCES THIRD QUARTER RESULTS
Next Article:MASSACHUSETTS STATE TREASURER TO ANNOUNCE DETAILS OF A $125 MILLION AFFORDABLE HOMEOWNERSHIP INITIATIVE WITH FANNIE MAE
Topics:


Related Articles
XOMA TO RECEIVE PAYMENTS AND REPORTS ON USES AND SALES OF HA-1A FOLLOWING INFRINGEMENT VERDICT
XOMA ANNOUNCES U.S. PATENT ON METHOD OF LINKING TWO KEY PORTIONS OF IMMUNOCONJUGATE DRUG PRODUCTS
ANTIBODY PRODUCTION ADVANCE REPORTED AT AMERICAN CHEMICAL SOCIETY MEETING
XOMA ANNOUNCES FDA REVIEW OF FIRST E5(R) MULTICENTER STUDY COMPLETED AND EUROPEAN PATENT ALLOWABILITY
XOMA AND CENTOCOR ANNOUNCE SETTLEMENT OF ALL OUTSTANDING LITIGATION AND DISPUTES
COURT DISMISSES SECURITIES CLAIMS AGAINST XOMA
XOMA ISSUED U.S. PATENT FOR BPI NEUTRALIZATION OF HEPARIN
MorphoSys and XOMA cross-license antibody technologies.
Biosite to engineer around XOMA patent.
Diversa Achieves Milestone Under XOMA Antibody Agreement.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters